8-K Announcements
6Material company update
May 14, 2026·SEC
Material company update
May 4, 2026·SEC
Material company update
Mar 31, 2026·SEC
Apellis Pharmaceuticals faces a critical transition period as it attempts to stabilize the commercial trajectory of Syfovre amidst significant revenue lumpiness and competitive pressures in the GA market. While the company has demonstrated the ability to achie...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth remains inconsistent, evidenced by a sharp decline from $458.6 million in 2025Q3 to $192.0 million in 2026Q1, despite maintaining a robust 78.9% gross margin.
Biogen has agreed to acquire Apellis Pharmaceuticals for $41.00 per share in cash, providing a significant premium and immediate value to shareholders.
Apellis Pharmaceuticals is set to discuss its fourth quarter and full year 2025 financial results in an upcoming conference call, which may highlight growth or profitability.
Apellis has emphasized its commercial execution and strategic priorities at a major healthcare conference, signaling confidence in its business trajectory.
Trailing total returns as of 10/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q2 2026Latest May 7, 2026 | $0.15+139.5% vs -$0.38 | $268M+27.5% vs $210M |
Q1 2026 Feb 24, 2026 | -$0.47-20.5% vs -$0.39 | $200M+0.3% vs $199M |
Q4 2025 Oct 30, 2025 | $1.67+62.1% vs $1.03 | $459M+130.1% vs $199M |
Q3 2025 Jul 31, 2025 | -$0.33+25.0% vs -$0.44 | $178M-52.0% vs $372M |
Benchmark APLS against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Apellis Pharmaceuticals, Inc. (APLS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $41.03 | $5.25B | 227.94 | 28.46% | 2.23% | 7.48% | — | |
| $15.22 | $1.5B | -2.61 | 20.13% | -81.79% | — | — | |
| $24.50 | $2.52B | -30.25 | 120.01% | -54.75% | -7.7% | — | |
| $54.65 | $4.5B | -14.57 | — | — | -30.58% | — | |
| $20.50 | $1.51B | 6.21 | 18.52% | 80.56% | 30.03% | — | |
| $1.74 | $2.88M | -0.03 | -81.82% | -370.05% | — | — |
Apellis Pharmaceuticals, Inc. (APLS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Apellis Pharmaceuticals, Inc. (APLS) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 14, 2026·SEC
May 4, 2026·SEC
Mar 31, 2026·SEC
Get notified when APLS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Apellis Pharmaceuticals, Inc. (APLS) stock FAQ — growth, dividends, profitability & financials explained
Apellis Pharmaceuticals, Inc. (APLS) reported $1.11B in revenue for fiscal year 2025.
Apellis Pharmaceuticals, Inc. (APLS) grew revenue by 28.5% over the past year. This is strong growth.
Yes, Apellis Pharmaceuticals, Inc. (APLS) is profitable, generating $133.3M in net income for fiscal year 2025 (2.2% net margin).
Apellis Pharmaceuticals, Inc. (APLS) has a return on equity (ROE) of 7.5%. This is below average, suggesting room for improvement.
Apellis Pharmaceuticals, Inc. (APLS) generated $37.8M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.